Can­del’s promis­ing Ph2 da­ta in pan­cre­at­ic can­cer; Mi­cro­bio­me biotech rais­es £27M

Plus, news about Man­i­fold and Phe­nomix:

Can­del Ther­a­peu­tics’ vi­ral im­munother­a­py im­press­es in pan­cre­at­ic can­cer: In a small Phase 2 tri­al for pa­tients with bor­der­line re­sectable pan­cre­at­ic can­cer, those who re­ceived Can­del’s ex­per­i­men­tal ther­a­py had 28.8 months of es­ti­mat­ed over­all sur­vival time com­pared to the 12.5 months in those who re­ceived stan­dard chemo. Four of sev­en pa­tients who re­ceived CAN-2409 were still alive at the March 29 da­ta cut-off, with two pa­tients sur­viv­ing more than four years from en­roll­ment. On­ly one out of six pa­tients who re­ceived chemother­a­py was still alive. Can­del’s stock $CADL rose near­ly 40% on Thurs­day morn­ing. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER